Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma
- PMID: 34339646
- DOI: 10.1016/S1470-2045(21)00326-0
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma
Conflict of interest statement
I declare no competing interests.
Comment in
-
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.Lancet Oncol. 2021 Aug;22(8):e343-e344. doi: 10.1016/S1470-2045(21)00419-8. Lancet Oncol. 2021. PMID: 34339647 No abstract available.
Comment on
-
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.Lancet Oncol. 2021 Jun;22(6):836-847. doi: 10.1016/S1470-2045(21)00097-8. Epub 2021 May 11. Lancet Oncol. 2021. PMID: 33989557
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical